Ipsen’s CEO to step down, names new chief executive

Publicado por en 22 Jul, 2016 en Noticias | Sin comentarios

The company said Garidel will assume the role of non-executive chairman and will advise Mayroy, the holding company for Ipsen.

David Meek has over 25 years of experience in the industry in pharmaceutical and biotechnology companies. Most recently, he was executive vice-president and president of the oncology division of Baxalta, which was recently acquired by Shire. David led the formation of the oncology division and rapidly created an innovative oncology portfolio through strategic acquisitions and partnering deals.

For 2015, Ipsen reported total sales of over €1.4 billion. The company sells more than 20 drugs in more than 115 countries.

Marc de Garidel, Chairman and CEO of Ipsen said: «Ipsen is currently performing well and could accelerate its growth in the coming years with the launch of Cabometyx in advanced kidney cancer and Telotristat etiprate in neuroendocrine tumors, in addition to strong prospects for Somatuline and Dysport with the new recently approved indications.»


Source: Pharmafile.com

Dejar una Respuesta

Tu dirección de correo electrónico no será publicada.

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

Aviso de cookies